The Kinase Chemogenomic Set (KCGS)

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Tool name: The Kinase Chemogenomic Set (KCGS)
• Research fields: Cancer
• Primary target: The list of kinases covered by the inhibitors in KCGS v1.0 and v2.0 can be found in the documentation section.
• Description: The Kinase Chemogenomic Set v2.0 (KCGS) is a collection of narrow spectrum, small molecule kinase inhibitors that has been assembled by the SGC-UNC to study the biology of dark kinases. It is the most diverse and highly annotated, publicly-available collection of kinase inhibitors. Version 1.0 of the set contained 187 kinase inhibitors sourced from eight pharma companies and academic laboratories with potent activity on 215 human kinases. Version 2.0 has replaced version 1.0, it features 295 compounds in total and covers 262 kinases. KCGS can help identify medically important kinases and allow the synthesis of high-quality chemical probes for high priority dark kinases of therapeutic interest. Dark kinases are those which are difficult to characterise, have little biological information gathered and their medical potential is unreached/untested. The goal of the KCGS is to generate, systematize and disseminate knowledge about dark kinases, biological networks in which they function and connections to cellular phenotypes and human disease. The KCGS aims to: (i) establish a knowledgebase covering the approximately 160 poorly understood dark kinases, (ii) distil primary data into functional biochemical and biological information and promote further research using genetic and chemical tools, which they are also developing and making available, (iii) place dark kinases within a new and emerging network-level understanding of cell signalling and physiology and (iv) identify those dark kinases whose mutation or mis-regulation is associated with human disease, making them possible therapeutic targets.
• Application: The Kinase Chemogenomic Set (KCGS) can be used to study the biology of dark kinases from the human genome and uncover new molecular targets for drug discovery.
• Additional notes: Each inhibitor has been screened across hundreds of kinases and only those meeting strict selective criteria are included in the set. For more information on KCGS or for commonly asked questions, please visit https://www.sgc-unc.org/faq.

Handling

• Storage conditions: -80° C
• Shipping conditions: Dry Ice

Target Details

• Primary target: The list of kinases covered by the inhibitors in KCGS v1.0 and v2.0 can be found in the documentation section.

Application Details

• Application: The Kinase Chemogenomic Set (KCGS) can be used to study the biology of dark kinases from the human genome and uncover new molecular targets for drug discovery.

References

• Blog on the release of KCGS v2.0
• KCGS FAQs
• Burdova et al. 2019. EMBO J. 38(20):e101443. PMID: 31424118.
• Wells et al. 2018. Medchemcomm. 9(1):44-66. PMID: 30108900.
• Drewry et al. 2017. PLoS One. 12(8):e0181585. PMID: 28767711.

Documentation

• KCGS 2.0 plate map & data
• KCGS 2.0 Plate Map set up